Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CNSP

Cns Pharmaceuticals Inc

May 22 • 04:00PM ET

5.42

+0.37 7.33 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: LIXT SHPH IMNN TNXP BCDA

Index	-	P/E	-	EPS (ttm)	-29.63	Insider Own	0.00%	Shs Outstand	0.81M	Perf Week	9.49%
Market Cap	7.92M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	-	Shs Float	-	Perf Month	119.43%
Enterprise Value	5.20M	PEG	-	EPS next Q	-0.24	Inst Own	9.96%	Short Float	-	Perf Quarter	73.16%
Income	-16.49M	P/S	-	EPS this Y	95.38%	Inst Trans	5.84%	Short Ratio	0.03	Perf Half Y	-19.47%
Sales	0.00M	P/B	62.21	EPS next Y	-0.61%	ROA	-179.17%	Short Interest	0.04M	Perf YTD	3.24%
Book/sh	0.09	P/C	2.68	EPS next 5Y	62.53%	ROE	-298.64%	52W High	14.76 -63.28%	Perf Year	-60.55%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	95.26% 85.25%	ROIC	-23317.01%	52W Low	1.90 185.26%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.92% 13.90%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.30%	Oper. Margin	-	ATR (14)	0.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.07	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	61.43%	SMA20	7.23%	Beta	0.79	Target Price	10.00
Payout	-	Debt/Eq	3.29	Sales Q/Q	-	SMA50	56.12%	Rel Volume	0.02	Prev Close	5.05
Employees	8	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	-5.39%	Avg Volume	1.40M	Price	5.42
IPO	Nov 08, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-35.94% -	Trades		Volume	23,011	Change	7.33%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy	$11

May-14-26 08:00AM	CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress (ACCESSWIRE) -9.24%
May-04-26 10:30AM	BC-Most Active Stocks (Associated Press) +239.23%
07:00AM	CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing (ACCESSWIRE)
Mar-11-26 08:35AM	CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline (ACCESSWIRE) -11.64%
Mar-02-26 08:25AM	CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team (ACCESSWIRE)
08:25AM	Loading…
Feb-17-26 08:25AM	CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation (ACCESSWIRE) -5.78%
Jan-27-26 09:00AM	CNS Pharmaceuticals Issues Letter to Shareholders (ACCESSWIRE)
Dec-17-25 07:00AM	CNS Pharmaceuticals Announces CEO Transition (ACCESSWIRE) -6.40%
Nov-17-25 08:35AM	CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-10-25 08:45AM	CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting (ACCESSWIRE)
Sep-13-25 09:05AM	CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap (TipRanks)
Sep-03-25 09:15AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (ACCESSWIRE)
Aug-15-25 08:05AM	CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE) -15.59%
Aug-14-25 09:15AM	CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (ACCESSWIRE) -11.19%
Jul-22-25 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (ACCESSWIRE)
08:40AM	Loading…
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-18-25 08:00AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -10.71%
Jul-09-25 09:32AM	CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Jun-24-25 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 (ACCESSWIRE)
Jun-05-25 08:05AM	CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit (ACCESSWIRE)
May-16-25 08:05AM	CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-13-25 09:35AM	CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.40%
07:00AM	CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 (ACCESSWIRE)
Apr-02-25 08:46AM	CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year (TipRanks)
Mar-25-25 08:00AM	CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme (ACCESSWIRE) -51.78%
Feb-26-25 09:05AM	CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing (ACCESSWIRE)
Feb-20-25 09:00AM	CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum (ACCESSWIRE) -10.50%
Feb-19-25 09:00AM	CNS Pharmaceuticals, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -41.19%
08:30AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Feb-18-25 09:00AM	CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit (ACCESSWIRE)
08:00AM	Loading…
Feb-10-25 08:00AM	CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference (ACCESSWIRE) +10.46%
Dec-05-24 09:10AM	CNS Pharmaceuticals to Host Virtual Analyst and Investor Day on December 11, 2024 (ACCESSWIRE)
09:10AM	CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 (ACCESS Newswire)
Nov-25-24 09:00AM	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -7.56%
Nov-18-24 08:55AM	CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) (ACCESSWIRE) +14.18%
Nov-15-24 09:10AM	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -11.61%
Nov-04-24 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment (ACCESSWIRE)
Nov-01-24 09:00AM	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (ACCESSWIRE)
Oct-23-24 02:50PM	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -10.02%
Oct-10-24 09:00AM	CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment (ACCESSWIRE)
Oct-08-24 09:15AM	CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC (ACCESSWIRE) +11.37%
Sep-23-24 09:00AM	CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum (ACCESSWIRE)
Sep-12-24 09:00AM	CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement (ACCESSWIRE) -5.58%
Sep-04-24 09:05AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Sep-03-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. (GlobeNewswire)
Aug-27-24 09:10AM	CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (ACCESSWIRE) -7.11%
Aug-22-24 09:15AM	CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Aug-15-24 08:00AM	CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-30-24 07:00AM	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies (ACCESSWIRE) -60.58%
Jul-25-24 09:05AM	CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-16-24 09:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE) -5.93%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.00%
Jul-03-24 11:10AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) +15.87%
Jun-26-24 08:00AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -35.21%
Jun-14-24 03:11PM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -22.93%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE) -27.72%
Jun-03-24 08:05AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -39.87%
May-20-24 08:30AM	CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (ACCESSWIRE)
May-16-24 11:53AM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) +12.68%
07:45AM	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results (ACCESSWIRE)
Apr-23-24 09:00AM	CNS Pharmaceuticals to Present at the LSX World Congress 2024 (ACCESSWIRE) +5.47%
Apr-22-24 10:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity (ACCESSWIRE)
Apr-01-24 11:52PM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) -14.54%
05:00PM	CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements (ACCESSWIRE)
09:05AM	CNS Pharmaceuticals to Present at Two Investor Conferences in April (ACCESSWIRE)
Jan-29-24 09:00PM	CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering (ACCESSWIRE) -20.94% -27.67%
Jan-18-24 08:45AM	Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors (ACCESSWIRE)
Jan-17-24 08:45AM	CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Dec-18-23 08:35AM	CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin (ACCESSWIRE) -23.12%
Dec-06-23 09:00AM	How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure (ACCESSWIRE)
Nov-22-23 09:05AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy (ACCESSWIRE) +7.66%
Nov-16-23 10:00AM	CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate (ACCESSWIRE) +9.38%
Nov-15-23 08:00AM	CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End (ACCESSWIRE) +14.97%
Oct-19-23 09:05AM	CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE) +11.24%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) +11.25%
Oct-16-23 09:00AM	Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope (ACCESSWIRE) +20.00%
Oct-11-23 08:45AM	CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date (ACCESSWIRE) +10.28%
Sep-07-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Sep-05-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE) -6.51%
Aug-14-23 08:35AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -12.81%
07:35AM	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones (ACCESSWIRE)
Aug-03-23 08:15AM	CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference (ACCESSWIRE)
08:00AM	CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Jul-27-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-05-23 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series (ACCESSWIRE)
Jun-14-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +9.00%
May-25-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
May-15-23 08:35AM	CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-08-23 08:45AM	Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors (ACCESSWIRE) -5.99%
May-03-23 08:45AM	CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC (ACCESSWIRE) +26.32%
Apr-27-23 08:45AM	CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study (ACCESSWIRE)
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +17.02%
Apr-10-23 08:45AM	Over 100 Patients Now Enrolled in CNS Pharmaceuticals (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Apr-06-23 09:05AM	CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (ACCESSWIRE) -13.38%
Apr-03-23 08:05AM	CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-29-23 09:05AM	CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event (PR Newswire)
Mar-13-23 07:05AM	CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues (PR Newswire) +6.40%
Mar-09-23 09:05AM	CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland (PR Newswire) -8.16%
Feb-07-23 08:45AM	CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire) -7.89%
Jan-12-23 08:45AM	CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland (PR Newswire) -8.12%

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

CTPMr. Christopher S. Downs CPA

PresidentMr. Rami Levin M.B.A.

Chief Financial OfficerMr. Steve O'Loughlin M.B.A.

M.Sc.Mr. Eric Faulkner M.B.A.

Chief Business OfficerMr. Dylan Wenke M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Charles Faith L.	Director	May 18 '26	Buy	4.79	7,100	34,002	7,100	May 20 09:03 AM

Open in Screener

ABEO

Abeona Therapeutics Inc

May 22 • 04:00PM ET

5.44

-0.08 -1.45 %

Healthcare • Biotechnology • USA • Small • NASD

ABEO Abeona Therapeutics Inc daily Stock Chart

Peers: RGNX EDIT QURE PGEN SGMO

| Held by: VTI IWM VXF SURI IWO VTWO ITOT IWC EES VTWG

Index	RUT	P/E	5.80	EPS (ttm)	0.94	Insider Own	12.07%	Shs Outstand	56.87M	Perf Week	-0.91%
Market Cap	310.05M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-4.09%	Shs Float	50.11M	Perf Month	-1.45%
Enterprise Value	164.95M	PEG	-	EPS next Q	-0.22	Inst Own	69.40%	Short Float	32.90%	Perf Quarter	5.02%
Income	66.14M	P/S	21.32	EPS this Y	-171.45%	Inst Trans	-2.20%	Short Ratio	13.24	Perf Half Y	29.52%
Sales	14.54M	P/B	2.13	EPS next Y	90.99%	ROA	44.41%	Short Interest	16.49M	Perf YTD	3.23%
Book/sh	2.55	P/C	1.84	EPS next 5Y	-26.72%	ROE	70.99%	52W High	7.54 -27.85%	Perf Year	-17.33%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	- -	ROIC	43.08%	52W Low	4.00 36.00%	Perf 3Y	67.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	60.26% -10.26%	Gross Margin	34.60%	Volatility	5.08% 4.93%	Perf 5Y	-86.57%
Dividend TTM	-	EV/Sales	11.34	EPS Y/Y TTM	246.52%	Oper. Margin	-637.92%	ATR (14)	0.27	Perf 10Y	-91.26%
Dividend Ex-Date	-	Quick Ratio	5.70	Sales Y/Y TTM	-100.00%	Profit Margin	454.86%	RSI (14)	49.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.89	EPS Q/Q	-24.83%	SMA20	-2.42%	Beta	1.34	Target Price	19.71
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	-	SMA50	5.50%	Rel Volume	0.54	Prev Close	5.52
Employees	226	LT Debt/Eq	0.06	Earnings	May 13 BMO	SMA200	1.76%	Avg Volume	1.25M	Price	5.44
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.45% 90.72%	Trades		Volume	671,515	Change	-1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

May-13-26 07:01PM	Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
07:35AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Abeona Therapeutics Reports First Quarter 2026 Results and Provides Pipeline Update (GlobeNewswire)
May-11-26 08:30AM	Abeona Therapeutics Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN (GlobeNewswire)
May-04-26 08:30AM	Abeona Therapeutics Announces Date of First Quarter Financial Results (GlobeNewswire) +9.58%
08:30AM	Loading…
May-01-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-26 08:30AM	Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors (GlobeNewswire)
Apr-06-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York (GlobeNewswire) +5.24%
Mar-20-26 08:30AM	Abeona Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-17-26 03:02PM	Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... (GuruFocus.com)
07:39AM	Abeona Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates (GlobeNewswire)
Mar-09-26 07:30AM	Abeona Therapeutics Provides Business Update Highlighting Building Momentum in ZEVASKYN Commercial Launch (GlobeNewswire) +6.39%
Mar-03-26 07:30AM	Abeona Therapeutics Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference (GlobeNewswire)
05:00AM	Loading…
Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-09-26 10:04AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-25 07:30AM	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer (GlobeNewswire) -5.22%
Dec-11-25 07:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas (GlobeNewswire)
Dec-08-25 07:30AM	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy (GlobeNewswire) +5.34%
Dec-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.72%
Nov-12-25 04:01PM	Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +18.47% -8.30%
11:37AM	Here's Why Abeona Therapeutics Popped Higher Today (Motley Fool)
07:40AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation (GlobeNewswire)
Nov-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 10:45AM	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) (GlobeNewswire)
Oct-20-25 08:30AM	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs (GlobeNewswire)
07:30AM	Loading…
Oct-13-25 07:30AM	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program (GlobeNewswire)
Oct-08-25 07:30AM	Abeona Therapeutics and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN Gene Therapy (GlobeNewswire) +5.52%
Oct-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-08-25 08:28AM	Should You Invest in Abeona Therapeutics (ABEO)? (Insider Monkey)
Sep-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Ph.D.Dr. Vishwas Seshadri M.B.A.

Chief Financial OfficerMr. Joseph Walter Vazzano CPA

Ph.D.Dr. Brendan M. O'Malley J.D.

Chief Technical & Scientific OfficerMr. Brian Kevany Ph.D.

Vice President of Investor Relations & Corporate CommunicationsMr. Gregory Gin

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alvino Mark	Director	May 22 '26	Sale	5.46	6,500	35,463	77,565	May 22 05:24 PM
Alvino Mark	Director	May 22 '26	Proposed Sale	5.46	6,500	35,463		May 22 04:12 PM
Crombez Eric	Director	May 15 '26	Sale	5.53	26,143	144,636	37,313	May 15 05:00 PM
Crombez Eric	Director	May 15 '26	Proposed Sale	5.53	26,143	144,636		May 15 04:29 PM
Vasanthavada Madhav	Chief Commercial Officer	May 11 '26	Sale	5.96	5,548	33,073	313,071	May 11 06:36 PM
Vasanthavada Madhav	Officer	May 11 '26	Proposed Sale	5.96	5,548	33,073		May 11 04:16 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '26	Sale	4.38	29,985	131,481	1,430,423	Mar 31 09:03 PM
Seshadri Vishwas	Officer	Mar 31 '26	Proposed Sale	4.38	29,985	131,481		Mar 31 04:42 PM
Vazzano Joseph Walter	Officer	Mar 16 '26	Proposed Sale	4.76	785	3,737		Mar 16 04:31 PM
Vazzano Joseph Walter	Chief Financial Officer	Mar 16 '26	Sale	4.76	785	3,737	567,775	Mar 16 04:29 PM
Silverstein Christine Berni	Director	Feb 02 '26	Proposed Sale	5.09	20,070	102,168		Feb 09 04:01 PM
Silverstein Christine Berni	Director	Feb 02 '26	Sale	5.09	20,070	102,168	137,722	Feb 04 04:30 PM
Wuchterl Donald A.	Director	Feb 02 '26	Sale	5.09	14,814	75,412	167,935	Feb 02 06:59 PM
Crombez Eric	Director	Feb 02 '26	Sale	5.09	16,284	82,895	63,456	Feb 02 06:55 PM
Wuchterl Donald A.	Director	Feb 02 '26	Proposed Sale	5.09	14,814	75,412		Feb 02 04:58 PM
Crombez Eric	Director	Feb 02 '26	Proposed Sale	5.09	16,284	82,886		Feb 02 04:43 PM
Alvino Mark	Director	Feb 02 '26	Proposed Sale	5.09	2,000	10,180		Feb 02 04:40 PM
Alland Leila	Director	Feb 02 '26	Proposed Sale	5.09	18,065	91,962		Feb 02 04:39 PM
Alland Leila	Director	Feb 02 '26	Sale	5.09	18,065	91,962	173,614	Feb 02 04:30 PM
Alvino Mark	Director	Feb 02 '26	Sale	5.09	2,000	10,181	84,065	Feb 02 04:30 PM
Vasanthavada Madhav	Chief Commercial Officer	Jan 22 '26	Sale	5.29	12,610	66,658	318,619	Jan 26 04:35 PM
Vazzano Joseph Walter	Chief Financial Officer	Jan 22 '26	Sale	5.33	18,666	99,507	568,560	Jan 22 08:34 PM
Seshadri Vishwas	Chief Executive Officer	Jan 22 '26	Sale	5.33	69,832	372,267	1,460,408	Jan 22 08:33 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jan 22 '26	Sale	5.33	13,578	72,383	451,134	Jan 22 08:33 PM
Vasanthavada Madhav	Officer	Jan 22 '26	Proposed Sale	5.29	12,610	66,658		Jan 22 04:10 PM
Vazzano Joseph Walter	Officer	Jan 22 '26	Proposed Sale	5.33	18,666	99,507		Jan 22 04:09 PM
O'Malley Brendan M.	Officer	Jan 22 '26	Proposed Sale	5.39	13,578	73,233		Jan 22 04:09 PM
Seshadri Vishwas	Officer	Jan 22 '26	Proposed Sale	5.33	69,832	372,267		Jan 22 04:08 PM
Alvino Mark	Director	Jan 21 '26	Sale	5.23	13,500	70,574	48,752	Jan 21 04:30 PM
Alvino Mark	Director	Jan 21 '26	Proposed Sale	5.23	13,500	70,574		Jan 21 04:10 PM
Seshadri Vishwas	Chief Executive Officer	Dec 29 '25	Sale	5.31	25,000	132,740	1,164,818	Dec 29 04:30 PM
Seshadri Vishwas	Officer	Dec 29 '25	Proposed Sale	5.31	25,000	132,695		Dec 29 04:00 PM
Alvino Mark	Director	Nov 13 '25	Sale	4.74	15,000	71,168	62,252	Nov 14 04:30 PM
Alvino Mark	Director	Nov 13 '25	Proposed Sale	4.74	15,000	71,168		Nov 13 04:06 PM
Seshadri Vishwas	Chief Executive Officer	Oct 16 '25	Sale	5.49	249	1,366	1,189,818	Oct 16 04:15 PM
Seshadri Vishwas	Officer	Oct 16 '25	Proposed Sale	5.49	249	1,366		Oct 16 04:09 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 29 '25	Sale	5.39	9,366	50,516	350,763	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 30 '25	Sale	5.24	25,000	130,930	1,190,067	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 29 '25	Sale	5.39	19,274	103,954	1,215,067	Oct 01 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 29 '25	Sale	5.39	9,035	48,730	453,631	Oct 01 04:30 PM
Seshadri Vishwas	Officer	Sep 29 '25	Proposed Sale	5.39	44,274	238,792		Sep 29 04:54 PM
O'Malley Brendan M.	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:44 PM
Vazzano Joseph Walter	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:31 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 22 '25	Sale	5.43	688	3,736	360,129	Sep 22 07:49 PM
O'Malley Brendan M.	Officer	Sep 22 '25	Proposed Sale	5.86	17,376	101,749		Sep 22 04:23 PM
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM
Silverstein Christine Berni	Director	Jul 09 '25	Sale	5.86	13,093	76,669	120,479	Jul 10 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '25	Sale	5.86	69,420	406,503	1,234,341	Jul 10 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '25	Sale	5.86	25,411	148,799	479,168	Jul 10 04:30 PM
Wuchterl Donald A.	Director	Jul 08 '25	Sale	5.82	5,176	30,147	145,436	Jul 10 04:30 PM
Charles Faith L.	Director	Jul 09 '25	Sale	5.86	10,738	62,879	139,094	Jul 10 04:30 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '25	Sale	5.86	17,428	102,053	360,817	Jul 10 04:30 PM
Alvino Mark	Director	Jul 09 '25	Sale	5.86	13,093	76,669	77,252	Jul 10 04:30 PM
Vazzano Joseph Walter	Officer	Jul 09 '25	Proposed Sale	5.86	25,335	148,354		Jul 09 04:55 PM
Seshadri Vishwas	Officer	Jul 09 '25	Proposed Sale	5.86	69,215	405,302		Jul 09 04:52 PM
O'Malley Brendan M.	Officer	Jul 09 '25	Proposed Sale	5.86	17,376	101,749		Jul 09 04:48 PM
Charles Faith L.	Director	Jul 09 '25	Proposed Sale	5.86	10,706	62,691		Jul 09 04:45 PM
Silverstein Christine Berni	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:40 PM
Alvino Mark	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:36 PM
Wuchterl Donald A.	Director	Jul 08 '25	Proposed Sale	5.82	5,176	30,147		Jul 08 04:06 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM

CNSP

Cns Pharmaceuticals Inc

ABEO

Abeona Therapeutics Inc

Upgrade your Finviz experience